See the DrugPatentWatch profile for trulicity
How Long Does Trulicity Stay in Your System?
Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist injection for type 2 diabetes. It has a half-life of about 5 days, meaning half the drug is eliminated every 5 days after subcutaneous injection.[1] Steady-state levels are reached after 4-5 weeks of weekly dosing, with the drug detectable in the body for up to 4-5 weeks after the last dose.[2]
Full clearance typically takes 25-30 days (about 5 half-lives), though this varies by individual factors like kidney function, age, and body weight.[1][3]
Factors Affecting Clearance Time
Kidney impairment slows elimination, as 97% of dulaglutide is metabolized via proteolytic degradation rather than renal excretion.[1] Liver issues have minimal impact. In clinical studies, exposure increased by 31% in mild kidney impairment and up to 94% in end-stage disease.[3] No dosage adjustment is needed for mild/moderate impairment, but it's not recommended in severe cases.
Detection in Tests or Blood
Trulicity isn't tested in standard drug screens (e.g., urine for opioids). Blood levels drop below therapeutic range (~0.1 mcg/mL) after 2-3 weeks post-dose, but trace amounts may linger longer via mass spectrometry.[2] No specific urine/blood cutoff data exists for detection windows.
What Happens If You Miss or Stop Doses?
Missing a dose means blood levels decline over ~5 days, potentially raising blood sugar. Restarting restores steady state in 4-5 weeks. Stopping abruptly doesn't cause overdose risk due to slow clearance, but monitor for hyperglycemia.[1][4]
Half-Life Compared to Other GLP-1 Drugs
| Drug | Half-Life | Dosing Frequency | Clearance Time |
|------|-----------|------------------|---------------|
| Trulicity (dulaglutide) | 5 days | Weekly | 4-5 weeks |
| Ozempic (semaglutide) | 1 week | Weekly | 5-6 weeks |
| Victoza (liraglutide) | 13 hours | Daily | 3-4 days |
| Mounjaro (tirzepatide)* | 5 days | Weekly | 4-5 weeks |
*Mounjaro is dual GLP-1/GIP; similar pharmacokinetics to Trulicity.[5]
Patients switching drugs should overlap or taper under medical guidance to avoid gaps in glucose control.
[1]: Trulicity Prescribing Information (FDA)
[2]: DrugBank: Dulaglutide Pharmacokinetics
[3]: Clinical Pharmacology Review (FDA)
[4]: Eli Lilly Trulicity Patient Guide
[5]: Mounjaro Prescribing Information (FDA)